Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
240 hedge funds and large institutions have $4.4B invested in Soleno Therapeutics in 2025 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 114 increasing their positions, 53 reducing their positions, and 49 closing their positions.
115% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 53
20% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 49
10.12% more ownership
Funds ownership: 112.61% → 122.73% (+10%)
3% more funds holding
Funds holding: 233 → 240 (+7)
7% less capital invested
Capital invested by funds: $4.75B → $4.4B (-$351M)
12% less call options, than puts
Call options by funds: $154M | Put options by funds: $175M
25% less funds holding in top 10
Funds holding in top 10: 16 → 12 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$346M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$125M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$95M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$63.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$56.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$161M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$125M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$78.2M |
| 4 |
CG
Carlyle Group
Washington,
District of Columbia
|
-$72.1M |
| 5 |
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Warszawa,
Poland
|
-$42.1M |
SLNO Hedge Fund Activity: Q3 2025 in Review
240 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2025, worth a combined $4.4B — down 7.4% from $4.75B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new SLNO positions and 49 closed out — a net gain of 10 holders — while 114 added to existing stakes and 53 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $346M. The largest seller was Adage Capital Partners, cutting an estimated $161M.
- 240 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2025, up from 233 in Q2 2025.
- Funds reported $4.4B of Soleno Therapeutics stock for Q3 2025, down 7.4% quarter-over-quarter.
- 59 funds opened new Soleno Therapeutics positions in Q3 2025 and 49 closed out, a net change of +10 holders.
- The largest Soleno Therapeutics buyer in Q3 2025 was Fidelity Investments, an estimated $346M added.
- The largest Soleno Therapeutics seller in Q3 2025 was Adage Capital Partners, an estimated $161M sold.
Based on aggregated 13F filings for Q3 2025.